Medindia

X

Replidyne to Announce Third Quarter 2007 Earnings

Tuesday, October 9, 2007 General News J E 4
Advertisement
LOUISVILLE, Colo., Oct. 9 Replidyne, Inc.(Nasdaq: RDYN) announced today that it will host a conference call and webcaston Tuesday, October 30, 2007 at 4:45 P.M. EDT to report third quarter 2007earnings. Callers may participate in the conference call by dialing800-435-1261 (domestic) or 617-614-4076 (international), and providing thepasscode 57078639.

A replay of the conference call will be available approximately one hourafter completion of the call through Tuesday, November 13, 2007 at midnight.Callers may access the replay by dialing 888-286-8010 (U.S. participants) or617-801-6888 (international participants). The audio replay passcode is69926592. To access a replay of the webcast, visit the Investor Relationssection of the company's website at http://www.Replidyne.com.

About Replidyne, Inc.

Replidyne is a biopharmaceutical company focused on discovering,developing, in-licensing and commercializing innovative anti-infectiveproducts. Replidyne's lead product, faropenem medoxomil, is a novel oralcommunity antibiotic, expected to be appropriate for use as a first-lineantibiotic for treatment of respiratory and skin infections in adult andpediatric patients. Replidyne's second drug candidate, REP8839, is a topicalanti-infective product candidate in development for the treatment of skin andwound infections, including methicillin-resistant S. aureus (MRSA) infections.Replidyne's investigational antibacterial agent REP3123 targets Gram-positiveC. difficile bacteria and C. difficile-associated disease (CDAD). Replidyneis pursuing the development of other novel anti-infective programs based onits in-house discovery research.

Safe Harbor

This press release contains plans, intentions, objectives, estimates andexpectations that constitute forward-looking statements about Replidyne, Inc.that involve significant risks and uncertainties. Actual results could differmaterially from those discussed due to a number of factors including, thesuccess and timing of pre-clinical studies and clinical trials; the Company'sability to obtain a new partner for faropenem on acceptable terms; theCompany's ability to obtain and maintain regulatory approval of productcandidates and the labeling under any approval that may be obtained; plans todevelop and commercialize product candidates; the loss of key scientific ormanagement personnel; the size and growth of the potential markets for theCompany's product candidates and the Company's ability to serve thosemarkets; regulatory developments in the U.S. and foreign countries; the rateand degree of market acceptance of any future products; the accuracy ofCompany estimates regarding expenses, future revenues and capitalrequirements; the Company's ability to obtain and maintain intellectualproperty protection for our product candidates; the successful development ofthe Company's sales and marketing capabilities; the success of competing drugsthat are or become available; and the performance of third party manufacturers.These and additional risks and uncertainties are described more fully in theCompany's most recent Form 10-Q filed with the SEC under the SecuritiesExchange Act of 1934. Copies of filings made with the SEC are availablethrough the SEC's electronic data gather analysis and retrieval system (EDGAR)at http://www.sec.gov. All forward-looking statements made in the pressrelease are made as of the date hereof and the Company assumes no obligationto update the forward-looking statements in the document.

SOURCE Replidyne, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Tandem Labs' New England Facility Doubles Discover...
S
Australian Therapeutics Goods Administration Appro...